Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 21.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,747 shares of the company’s stock after acquiring an additional 4,692 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Roivant Sciences were worth $307,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences during the second quarter worth about $34,000. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences during the 2nd quarter worth approximately $36,000. Quarry LP acquired a new stake in Roivant Sciences during the 2nd quarter worth approximately $53,000. Acadian Asset Management LLC purchased a new position in Roivant Sciences in the 1st quarter valued at approximately $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Roivant Sciences in the second quarter worth $101,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at approximately $7,193,525.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Keith S. Manchester sold 368,052 shares of Roivant Sciences stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $11.62, for a total value of $4,276,764.24. Following the sale, the director now owns 1,412,126 shares of the company’s stock, valued at $16,408,904.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the transaction, the chief operating officer now owns 617,470 shares in the company, valued at $7,193,525.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,577,309 shares of company stock valued at $42,151,184 over the last quarter. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Up 1.1 %

Shares of NASDAQ:ROIV opened at $11.68 on Monday. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The firm has a 50 day simple moving average of $11.82 and a 200-day simple moving average of $11.26. The company has a market capitalization of $8.64 billion, a PE ratio of 2.10 and a beta of 1.24. Roivant Sciences Ltd. has a twelve month low of $8.47 and a twelve month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.33. The company had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business’s quarterly revenue was up 155.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.38) earnings per share. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Finally, Piper Sandler lifted their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $17.39.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.